Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients

Clinical Nephrology

Volumn 71, Issue 2, 2009, Pages 207-213

  Aladren Regidor M J ^a,b  

^a Hospital Ernest Lluch   (Spain)

^b NONE   (Spain)

Author keywords

Calcification; Cinacalcet; Secondary hyperparathyroidism (SHPT)

Indexed keywords

ALKALINE PHOSPHATASE; AMLODIPINE; BISOPROLOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; ERYTHROPOIETIN; IRON; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; NAPHTHALENE DERIVATIVE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE RADIOGRAPHY; BRONCHOSCOPY; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CASE REPORT; DIET THERAPY; DRUG MEGADOSE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; LUNG ALVEOLUS WALL; MALE; METABOLIC DISORDER; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID SCINTISCANNING; PHOSPHATE METABOLISM; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN RESTRICTION; QUALITY OF LIFE; SECONDARY HYPERPARATHYROIDISM; SOFT TISSUE CALCIFICATION; SUPPLEMENTATION; THORAX RADIOGRAPHY; TREATMENT RESPONSE; CHRONIC KIDNEY FAILURE; RENAL REPLACEMENT THERAPY;

ADULT; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; NAPHTHALENES; RENAL DIALYSIS;

EID: 64549111819     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp71207     Document Type: Article

References (24)

1. Apostolou T, Damianou L, Kotsiev V, Drakopoulos S, Hadjiconstantinou V. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin Nephrol. 2006; 65: 374-377.
2. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38: 938-942.
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
4. Braun, J. Extraosseous calcification in patients with chronic renal failure. No escape? Nephrol Dial Transplant. 2005; 20: 2054-2059.
5. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004; 19: 1489-1496.
6. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D.. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005; 67: 467-476.
7. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 68: 1793-1800.
8. Dorsch O. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism. Nephrol Dial Transplant. 2007; 22: 637-640.
9. Decleire PY, Devogelaer JP, Goffin E. Cinacalcet improves bone mineral density in a renal transplant recipient with persistent hyperparathyroidism. Clin Nephrol. 2008; 69: 231-232.
10. Fiedler R, Deuber HJ, Langer T, Osten B, Mohan S, Jehle PM.. Effects of reduced dialysate Ca on Ca-P product and bone metabolism in hemodialysis patients. Nephron Clin Pract. 2004; 96: c3-c9.
11. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with car diac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131-2138.
12. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D. 1,25-dihydroxyvitamin D3 but not cinacalcet HCl treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant. 2005; 20: 1370-1377.
13. Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-dihydroxy D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998; 98: 1302-1306.
14. Lopez I, Aguilera-Tejero, E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol. 2006; 17: 795-804.
15. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945-1953.
16. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005; 67: 760-771.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl 3): S1-S201.
18. Serra AL, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, Wüthrich RP. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant. 2007; 22: 577-583.
19. Sterrett JR, Strom J, Stummvoll HK, Bahner U, Disney A, Soroka SD, Corpier C, Arruda JA, Schwanauer LE, Klassen PS, K. A. Olson, Block GA. Cinacalcet HCl (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2007; 68-01: 10-17.
20. Unbehaun R, Lauerwald W. Successful use of cinacalcet HCI in a patient with end stage renal failure and refractory secondary hyperparathyroidism due to parathyromatosis. Clin Nephrol. 2007; 67-03: 188-192.
21. Ureña Torres, P. Clinical experience with cinacalcet HCL. Nephrol Dial Transplant. 2004; 19: v27-v33.
22. Wada M, Nagano N. Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transplant. 2003; 18: III13-III17.
23. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004; 66: 2293-2299.
24. Yildiz A, Oflaz H, Pusuroglu H, Mercanoglu F, Genchallac H, Akkaya V, Ikizler TA, Sever MS. Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis patients. Am J Kidney Dis. 2003; 41: 616-623.